[{"id":"371d58a2-25f1-4a65-ae93-d66ba3aa87c2","acronym":"DEPLETHINK","url":"https://clinicaltrials.gov/study/NCT03466320","created_at":"2021-01-18T17:05:05.194Z","updated_at":"2024-07-02T16:36:30.744Z","phase":"Phase 1/2","brief_title":"DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2","source_id_and_acronym":"NCT03466320 - DEPLETHINK","lead_sponsor":"Celyad Oncology SA","biomarkers":" TP53 • NKG2D","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • NKG2D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CYAD-01 • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 09/18/2018","start_date":" 09/18/2018","primary_txt":" Primary completion: 02/01/2021","primary_completion_date":" 02/01/2021","study_txt":" Completion: 02/01/2021","study_completion_date":" 02/01/2021","last_update_posted":"2021-05-04"}]